<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003037</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-L102</org_study_id>
    <nct_id>NCT05003037</nct_id>
  </id_info>
  <brief_title>Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Open-label, Single Center, Phase II Study of Surufatinib Combined With Toripalimab and Chemotherapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li Zhang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab&#xD;
      and Chemotherapy as a first-line treatment in patients with advanced non-squamous non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Wild-type Genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EGFR mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin</intervention_name>
    <description>Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.</description>
    <arm_group_label>EGFR mutation</arm_group_label>
    <arm_group_label>Wild-type Genotype</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary provision of informed consent.&#xD;
&#xD;
          2. Males or females aged 18-75.&#xD;
&#xD;
          3. Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage&#xD;
             IIIB-Ⅳ).&#xD;
&#xD;
          4. At least one lesion can be measured by imaging.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.&#xD;
&#xD;
          6. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          7. None previous chemotherapy or targeted therapy(Arm:wild-type genotype).&#xD;
&#xD;
          8. Patients should be confirmed acquired EGFR T790M mutation and received adequate&#xD;
             EGFR-TKI treatment(Arm:EGFR mutation).&#xD;
&#xD;
          9. Female of childbearing age must have a negative pregnancy test (serum or urine) within&#xD;
             7 days before enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histological or cytologically confirmed small cell lung cancer (SCLC), including lung&#xD;
             cancer mixed with SCLC and NSCLC.&#xD;
&#xD;
          2. Diagnosed with other malignant diseases other than NSCLC within 5 years.&#xD;
&#xD;
          3. Have participated in other interventional clinical research treatments now or within 4&#xD;
             weeks.&#xD;
&#xD;
          4. Have previously received multi-targeted kinase inhibitors therapy.&#xD;
&#xD;
          5. Have active autoimmune diseases requiring systemic treatment within 2 years.&#xD;
&#xD;
          6. Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks.&#xD;
&#xD;
          7. Clinically uncontrollable pleural effusion/abdominal effusion.&#xD;
&#xD;
          8. Vaccinated vaccines or attenuated vaccines within 4 weeks before the group;&#xD;
&#xD;
          9. Pregnant or breastfeeding females.&#xD;
&#xD;
         10. Other serious hazards to the safety of patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenfeng Fang, MD.</last_name>
    <phone>+86-15322302066</phone>
    <email>fangwf@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang Dong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenfeng Fang, MD.</last_name>
      <phone>+86-15322302066</phone>
      <email>fangwf@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

